Company intelligence / Profile preview

HC Bioscience

Boston/Cambridge, Massachusetts, United Stateshcbioscience.com ↗

Ownership: Private
Employees: ~50
Development stage: Preclinical

Overview

The company developed a proprietary tRNA-based protein editing platform aimed at correcting disease-causing mutations at the translational level without altering DNA or mRNA. Lead programs targeted hemophilia A and Duchenne muscular dystrophy. After reviewing preclinical animal model data—particularly challenges with targeted delivery—the company decided to discontinue development and shut down operations as of March 2025. No clinical results were published.

Therapeutic areas: OncologyHematologyRare Diseases
Modalities: tRNA-based therapeuticsRNA-based therapeuticsprotein editing therapies
Industry: Biotech

Partnerships

– No major pharma partnerships publicly disclosed; open to strategic collaborations [3]

Beyond the preview

Go deeper on HC Bioscience.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HC Bioscience.

Explore the full profile